Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality ...

Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target, while ...

Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for its unbuzzd dietary supplement. What Happened: Quantum BioPharma announced ...

Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms ...

Biopharma had quite the September — and a strong quarter. The seemingly floundering and loss-plagued biopharma sector posted another month of strong gains in September, capping a remarkable quarter of ...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR ...

INDIANAPOLIS (WISH) — INCOG BioPharma Services announced Tuesday it will invest approximately $200 million in its manufacturing facility in Fishers to expand its injectable drug product manufacturing ...

Can-Fite BioPharma Ltd. CANF shares are up on Wednesday following the company’s announcement that its drug, Namodenoson, ...

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and significant de-risking from Shanghai Allist Pharmaceuticals commercialization. Firmonertinib has ...